^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lomvastomig (RG7769)

    i
    Other names: RG7769, RO7121661, RO-7121661, RO 7121661
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    PD1 inhibitor, TIM-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=134, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    lomvastomig (RG7769)
    6ms
    A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=134, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Apr 2024 --> Aug 2024 | Trial primary completion date: Apr 2024 --> Aug 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    lomvastomig (RG7769)
    over1year
    A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
    P2, N=210, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
    |
    CD8 expression • LAG3 expression
    |
    Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
    over2years
    A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
    P2, N=210, Recruiting, Hoffmann-La Roche | Trial completion date: Oct 2024 --> May 2025 | Trial primary completion date: Oct 2024 --> May 2025
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
    |
    CD8 expression • LAG3 expression
    |
    Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
    over3years
    A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
    P2, N=255, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
    |
    CD8 expression • LAG3 expression
    |
    Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
    over3years
    MORPHEUS mUC: Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (clinicaltrials.gov)
    P1/2, N=735, Recruiting, Hoffmann-La Roche | N=385 --> 735
    Clinical • Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • lomvastomig (RG7769)
    over3years
    A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
    P2, N=255, Not yet recruiting, Hoffmann-La Roche
    Clinical • New P2 trial • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
    |
    CD8 expression • LAG3 expression
    |
    Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
    4years
    MORPHEUS mUC: Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (clinicaltrials.gov)
    P1/2, N=385, Recruiting, Hoffmann-La Roche | Trial completion date: Mar 2023 --> Nov 2024 | Trial primary completion date: Sep 2020 --> Nov 2024
    Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • lomvastomig (RG7769)
    4years
    MORPHEUS mUC: Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (clinicaltrials.gov)
    P1/2, N=385, Recruiting, Hoffmann-La Roche | Trial completion date: Feb 2021 --> Mar 2023
    Clinical • Trial completion date • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • lomvastomig (RG7769)
    over4years
    [VIRTUAL] RG7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint inhibition to reactivate dysfunctional T cells (AACR-II 2020)
    P1 | "RG7769 binds to PD-1 with higher affinity than pembrolizumab and nivolumab. In summary, these preclinical data support the use of RG7769 as a monotherapy and as combination partner for the treatment of patients with solid/hematological tumors. A phase I study is currently ongoing in patients with advanced metastatic solid tumors (NCT03708328)."
    Checkpoint inhibition
    |
    PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • FCGR2A (Fc fragment of IgG receptor IIa)
    |
    PD-1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • lomvastomig (RG7769)
    almost5years
    MORPHEUS mUC: Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (clinicaltrials.gov)
    P1/2, N=305, Recruiting, Hoffmann-La Roche | Trial completion date: Aug 2023 --> Feb 2021
    Clinical • Trial completion date • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • lomvastomig (RG7769)